Table 1 Patient characteristics.

From: Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients

Measure

Autograft CPC

All

Positive

Negative

p valuea

(N = 416)

(N = 75)

(N = 341)

Gender, n (%)

   

0.70

 Male

236 (57)

41 (55)

195 (57)

 

 Female

180 (43)

34 (45)

146 (43)

 

Age at autoHCT (years)

   

0.032b

 Median (Range)

62.4 (31.7–83.0)

63.8 (43.5–83.0)

62.1 (31.7–79.9)

 

Year of autoHCT, n (%)

   

0.013

 2008–2011

55 (13)

17 (23)

38 (11)

 

 2012–2018

361 (87)

58 (77)

303 (89)

 

Induction treatment, n (%)

    

 VRD

159 (40)

18 (24)

141 (42)

0.004

 VCD

64 (16)

14 (19)

50 (15)

0.38

 KRD

64 (16)

11 (15)

53 (16)

1.00

 VD

71 (17)

16 (21)

55 (16)

0.31

 VTD

6 (1)

4 (5)

2 (1)

0.011

 Chemotherapy

16 (4)

2 (3)

14 (4)

0.75

 RD

15 (4)

7 (9)

8 (2)

0.009

 Other

18 (4)

3 (4)

15 (4)

1.00

Duration of induction, Median (days)

107.0 (19–511)

106.5 (22–511)

111.5 (19–495)

0.37b

Mobilization type, n (%)

   

0.39

 No chemotherapy

348 (84)

60 (80)

288 (84)

 

 Chemotherapy

68 (16)

15 (20)

53 (16)

 

ISS, n (%)

   

0.48

 I

118 (34)

17 (27)

101 (35)

 

 II

122 (35)

24 (39)

98 (34)

 

 III

107 (31)

21 (34)

86 (30)

 

 Unknown

69

13

56

 

RISS, n (%)

   

0.19

 I

49 (16)

5 (9)

44 (17)

 

 II

203 (65)

35 (65)

168 (65)

 

 III

59 (19)

14 (26)

45 (18)

 

 Unknown

105

21

84

 

KPS, n (%)

   

0.24

 <90

165 (42)

35 (49)

130 (41)

 

 ≥90

227 (58)

37 (51)

190 (59)

 

 Unknown

24

3

21

 

HCT-CI, n (%)

   

0.45

 ≤3

321 (77)

55 (73)

266 (78)

 

 >3

95 (23)

20 (27)

75 (22)

 

Conditioning regimen, n (%)

   

0.73

 Bu/Mel based

71 (17)

14 (19)

57 (17)

 

 Mel

345 (83)

61 (81)

284 (83)

 

Response prior to autoHCT, n (%)

   

<0.001

 sCR/CR

55 (13)

1 (1)

54 (16)

 

 nCR/VGPR

179 (43)

23 (31)

156 (46)

 

 PR

135 (32)

31 (41)

104 (30)

 

 SD

13 (3)

3 (4)

10 (3)

 

 PD

17 (23)

17 (5)

  

MRD prior to autoHCT, n (%)

   

<0.001

 Negative

134 (34)

6 (8)

128 (40)

 

 Positive

261 (66)

66 (92)

195 (60)

 

 Unknown

21

3

18

 

del 17p, n (%)

   

0.007

 Negative

259 (69)

35 (55)

224 (72)

 

 Positive

115 (31)

29 (45)

86 (28)

 

 NA

42

11

31

 

t(4;14), n (%)

   

0.71

 Negative

114 (59)

22 (63)

92 (58)

 

 Positive

79 (41)

13 (37)

66 (42)

 

 NA

223

40

183

 

t(14;16), n (%)

   

0.24

 Negative

97 (78)

18 (90)

79 (76)

 

 Positive

27 (22)

2 (10)

25 (24)

 

 NA

292

55

237

 

Any 1q+, n (%)

   

<0.001

 Negative

203 (49)

51 (68)

152 (45)

 

 Positive

213 (51)

24 (32)

189 (55)

 

Maintenance therapy, n (%)

   

0.24

 Len alone/RD

176 (42)

25 (33)

151 (44)

 

 PI alone

50 (12)

7 (9)

43 (13)

 

 Len+PI

41 (10)

9 (12)

32 (9)

 

 Len+Elo

29 (7)

5 (7)

24 (7)

 

 IMid alone

3 (1)

1 (1)

2 (1)

 

 None

117 (28)

28 (37)

89 (26)

 
  1. CPC clonal plasma cells, n number, autoHCT autologous hematopoietic stem cell transplant, VRD bortezomib, lenalidomide, dexamethasone, VCD bortezomib, cyclophosphamide, dexamethasone, KRD carfilzomib, lenalidomide, dexamethasone, VD bortezomib, dexamethasone, VTD bortezomib, thalidomide, dexamethasone, RD lenalidomide, dexamethasone, KPS karnofsky performance status, sCR stringent complete response, CR complete response, VGPR very good partial response, PR partial response, SD stable disease, PD progressive disease, MRD minimal residual disease, NA not available, Len lenalidomide, PI proteasome inhibitor, ELO elotuzumab.
  2. aFisher’s exact test or generalization.
  3. bWilcoxon rank-sum test.
Back to article page